AKTX
Akari Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.81 / 10
Netural
Fund flow rating stands at 7.62/10, showing robust capital inflow, although trends at various scales are mixed. Analyst sentiment is overwhelmingly bullish with a Strong Buy rating from one analyst, yet historical win rates are low, suggesting cautious optimism.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-05
InstitutionLadenburg Thalmann
Times predicted1
Historical Win Rate0.0%
Is money flowing into or out of AKTX?
- AKTX holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.81/10 (Netural).
